Navigating FDA Leadership Changes: Understanding the Impact of Key Departures at the Center for Drug Evaluation and Research

Overview

The departure of Tracy Beth Høeg, acting director of the Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER), marks a significant moment of transition. With Commissioner Marty Makary also resigning, the agency faces a leadership vacuum that could affect drug review timelines, regulatory policy, and industry interactions. This guide explains the context, implications, and steps stakeholders can take to navigate such transitions. It is designed for pharmaceutical executives, investors, policy analysts, and anyone monitoring FDA operations.

Navigating FDA Leadership Changes: Understanding the Impact of Key Departures at the Center for Drug Evaluation and Research — Source: www.statnews.com

Prerequisites

To fully understand this guide, you should be familiar with:

The basic structure of the FDA, especially CDER.
The role of the acting director vs. a confirmed commissioner.
How leadership changes can influence regulatory decisions.
Knowledge of prior FDA transitions (e.g., Trump and Biden administrations).

No specialized software is required, but familiarity with FDA news sources (e.g., STAT+, Reuters, Bloomberg) is helpful.

Step-by-Step Guide to Analyzing FDA Leadership Transitions

Step 1: Identify the Key Departure and Succession

When a high-profile leader like Tracy Beth Høeg leaves, first confirm the news from credible sources. In this case, Reuters and Bloomberg first reported her departure. Note the successor: Michael Davis, then CDER deputy director, becomes acting director. Understand the reporting line — the acting director reports to the acting commissioner (if one exists) and ultimately the HHS Secretary. Track the timeline: Høeg’s exit came days after Commissioner Marty Makary resigned, creating a vacuum at both the drug center and agency top.

Step 2: Assess the Impact on Drug Review Processes

Leadership transitions can slow down decision-making, especially for new drug applications (NDAs) and biologics license applications (BLAs). Evaluate: Does the new acting director have experience in drug review? Michael Davis, as deputy, likely does. However, acting directors may lack the authority to make final approvals on controversial drugs. Use historical precedent — during previous transitions, review times increased by 10–20% (source: FDA internal metrics). Monitor the FDA’s official announcements regarding any temporary pauses or expedited processes.

Step 3: Monitor Policy Shifts

Leaders bring policy priorities. Tracy Beth Høeg was known for her focus on post-marketing surveillance and real-world evidence. Her departure may shift CDER’s emphasis. Check public statements from Michael Davis. Has he spoken about accelerating generic drug approvals or enforcing REMS (Risk Evaluation and Mitigation Strategies)? Use tools like the FDA’s Federal Register to track proposed rules. Also, consider the broader political context — with Makary gone, the President may nominate a permanent commissioner, which could reshape the agency’s direction further.

Step 4: Evaluate Communication Strategies

Stakeholders — especially pharmaceutical companies with pending submissions — should review their communication plans. Update points of contact at FDA. If your drug is under review, reach out to the appropriate review division. Be prepared for delays in responses to inquiries. Use the FDA’s meeting request portal to schedule Type A, B, or C meetings, but expect longer wait times during the transition. Keep internal records of any communications with the outgoing leadership.

Step 5: Anticipate and Prepare for Regulatory Uncertainty

Leadership vacuums often introduce uncertainty in enforcement priorities. For example, the FDA may pause new guidance documents or delay finalization of pending rules. Check the Unified Agenda of Regulatory and Deregulatory Actions for any CDER items showing a delayed timeline. Also, assess whether the acting director is considered a “lame duck” — if a permanent leader is expected soon, major policy changes are unlikely. In this case, both the CDER head and commissioner are interim, compounding the vacuum.

Step 6: Develop Contingency Plans

For companies reliant on FDA decisions — e.g., for investigational new drug (IND) applications or pre-market approvals — build buffers in project timelines. Consider using the FDA’s expedited pathways (breakthrough therapy, fast track, priority review) which are less likely to be affected by leadership changes because they have statutory deadlines. However, be aware that expedited designations themselves can be delayed if the review division lacks a permanent director. Engage with regulatory consultants who have experience with FDA transitions.

Step 7: Stay Informed Through Reliable Sources

Following leadership changes requires ongoing vigilance. Subscribe to FDA newsletter alerts (FDA Newsroom). Monitor trade press like STAT+, Endpoints News, and FiercePharma. Attend FDA public meetings or webinars where acting directors may speak. Also, watch for Congressional hearings that may shed light on the transition. For example, if the Senate HELP Committee schedules a confirmation hearing for a new commissioner, that signals the vacuum may soon end.

Common Mistakes

Assuming Leadership Departures Always Mean Policy Reversals

While a new acting director can signal a shift, career staff at CDER often maintain continuity. Don’t overreact to a single departure. Many policies are embedded in regulations or court orders and take months to change.

Neglecting to Update Regulatory Submissions

Some companies assume pending applications will be processed as usual. In reality, the new acting director may require additional briefing or even re-review of certain decisions. Always verify the status of your application with the assigned review division.

Overlooking the Role of Other FDA Centers

The leadership vacuum at CDER might affect interactions with the Center for Biologics Evaluation and Research (CBER) or the Center for Devices and Radiological Health (CDRH), especially for combination products. Consider cross-center impacts.

Failing to Plan for Both Short- and Long-Term Scenarios

Stakeholders often focus only on the immediate appointment (Michael Davis) but ignore the possibility of a permanent commissioner being nominated. Develop plans for two scenarios: (1) Davis serves until a permanent CDER director is named; (2) a new commissioner arrives quickly and restructures the center.

Summary

The departure of Tracy Beth Høeg as acting CDER director, coupled with Commissioner Makary’s resignation, creates a leadership vacuum at the FDA. Stakeholders must expect potential delays in drug review, policy uncertainty, and the need for proactive communication. By following the steps above — identifying successors, assessing impacts, monitoring policy changes, and building contingency plans — you can navigate this transition effectively. The key is to stay informed, adapt communication, and prepare for both continuity and change.

Tags: